Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ALEMBIC PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ALEMBIC PHARMA DIVIS LABORATORIES/
ALEMBIC PHARMA
 
P/E (TTM) x 60.4 19.5 308.9% View Chart
P/BV x 13.9 7.5 184.5% View Chart
Dividend Yield % 0.4 0.5 86.9%  

Financials

 DIVIS LABORATORIES   ALEMBIC PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
ALEMBIC PHARMA
Mar-19
DIVIS LABORATORIES/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs1,639664 246.9%   
Low Rs1,115412 270.4%   
Sales per share (Unadj.) Rs186.3208.7 89.3%  
Earnings per share (Unadj.) Rs51.031.0 164.4%  
Cash flow per share (Unadj.) Rs57.337.1 154.5%  
Dividends per share (Unadj.) Rs16.005.50 290.9%  
Dividend yield (eoy) %1.21.0 113.7%  
Book value per share (Unadj.) Rs261.8144.2 181.5%  
Shares outstanding (eoy) m265.47188.52 140.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.42.6 286.6%   
Avg P/E ratio x27.017.4 155.7%  
P/CF ratio (eoy) x24.014.5 165.7%  
Price / Book Value ratio x5.33.7 141.0%  
Dividend payout %31.417.7 177.0%   
Avg Mkt Cap Rs m365,592101,461 360.3%   
No. of employees `00011.8NA-   
Total wages/salary Rs m5,4237,467 72.6%   
Avg. sales/employee Rs Th4,175.1NM-  
Avg. wages/employee Rs Th457.7NM-  
Avg. net profit/employee Rs Th1,141.8NM-  
INCOME DATA
Net Sales Rs m49,46339,347 125.7%  
Other income Rs m1,55694 1,659.2%   
Total revenues Rs m51,01939,441 129.4%   
Gross profit Rs m18,7188,736 214.3%  
Depreciation Rs m1,6891,152 146.6%   
Interest Rs m35184 19.0%   
Profit before tax Rs m18,5517,493 247.6%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0231,568 320.5%   
Profit after tax Rs m13,5275,844 231.5%  
Gross profit margin %37.822.2 170.5%  
Effective tax rate %27.120.9 129.4%   
Net profit margin %27.314.9 184.1%  
BALANCE SHEET DATA
Current assets Rs m46,50119,577 237.5%   
Current liabilities Rs m8,46814,896 56.8%   
Net working cap to sales %76.911.9 646.3%  
Current ratio x5.51.3 417.9%  
Inventory Days Days13190 145.8%  
Debtors Days Days8645 189.3%  
Net fixed assets Rs m25,79727,097 95.2%   
Share capital Rs m531377 140.8%   
"Free" reserves Rs m68,96226,811 257.2%   
Net worth Rs m69,49327,188 255.6%   
Long term debt Rs m04,993 0.0%   
Total assets Rs m80,38347,778 168.2%  
Interest coverage x531.041.7 1,273.4%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.60.8 74.7%   
Return on assets %16.912.6 133.7%  
Return on equity %19.521.5 90.6%  
Return on capital %26.723.6 113.3%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23819,453 212.0%   
Fx outflow Rs m12,4056,065 204.5%   
Net fx Rs m28,83313,388 215.4%   
CASH FLOW
From Operations Rs m9,5438,120 117.5%  
From Investments Rs m-6,854-7,556 90.7%  
From Financial Activity Rs m-2,459590 -416.6%  
Net Cashflow Rs m2301,153 19.9%  

Share Holding

Indian Promoters % 52.0 74.1 70.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 2.9 406.9%  
FIIs % 19.0 9.1 208.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 13.9 123.7%  
Shareholders   31,796 49,328 64.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   ELDER PHARMA  FDC  SUN PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  

Compare DIVIS LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 15, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES - ALEMBIC COMPARISON

COMPARE DIVIS LABORATORIES WITH

MARKET STATS